Dymon Asia Capital Singapore PTE. LTD. Takes Position in Protagonist Therapeutics, Inc. $PTGX

Dymon Asia Capital Singapore PTE. LTD. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, Holdings Channel.com reports. The firm acquired 10,000 shares of the company’s stock, valued at approximately $873,000.

Several other hedge funds have also recently bought and sold shares of PTGX. Jennison Associates LLC purchased a new stake in Protagonist Therapeutics during the fourth quarter worth about $28,924,000. Farallon Capital Management LLC lifted its position in shares of Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after purchasing an additional 24,000 shares in the last quarter. Mangrove Partners IM LLC boosted its stake in shares of Protagonist Therapeutics by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 478,413 shares of the company’s stock valued at $31,781,000 after purchasing an additional 83,030 shares during the period. Eagle Health Investments LP purchased a new position in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $5,005,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $391,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PTGX shares. Truist Financial upped their target price on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. JPMorgan Chase & Co. boosted their price target on shares of Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $110.00 price objective on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.21.

Protagonist Therapeutics Trading Down 0.0%

Shares of PTGX opened at $109.78 on Friday. Protagonist Therapeutics, Inc. has a twelve month low of $49.38 and a twelve month high of $111.78. The firm’s fifty day simple moving average is $101.71 and its 200-day simple moving average is $93.22. The firm has a market capitalization of $7.06 billion, a price-to-earnings ratio of -60.65 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The firm had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. On average, analysts predict that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the completion of the transaction, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bryan Giraudo sold 6,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the sale, the director directly owned 31,825 shares in the company, valued at $3,182,500. This trade represents a 15.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 272,345 shares of company stock worth $27,676,386 over the last three months. Company insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.